SOHM Inc.’s (SHMN) New Gene-Editing Technology Holds Potential to Revolutionize the Field of Cardiology, With Superior Capabilities Over Other Gene-Editing Systems
SOHM recently acquired ABBIE, a world-class gene-editing platform capable of inserting larger DNA sequences, including full genes, into a desired location of the target cell’s genome ABBIE is poised to facilitate drug development, with SOHM confident that its new gene-editing technology can revolutionize the field of cardiology by supporting new ways of discovering and developing drugs The ABBIE platform system is easy to operate and boasts high efficiency, low cost, and simple design ABBIE improves on some of the shortcomings of CRISPR-Cas9 as well as other gene-editing technologies, such as enabling researchers to edit genes of a large number of…